Estamos realizando la búsqueda. Por favor, espere...
1583
37
170
29213
4419
2602
347
390
Abstract: Background: The purpose of this study was to learn about the clinical practice of specialists who care for patients with giant cell arteritis, to verify whether they follow the diagnosis and treatment recommendations for this disease, and to identify areas for improvement. Methods: A cross-sectional survey on clinical practice in 2019. The survey was completed by 167 physicians (64% rheumatologists, 27% internal medicine specialists, and 9% other specialists) who attended a course on updating giant cell arteritis treatment. We compared the clinical practice collected in the study with the latest recommendations approved by the European League Against Rheumatism (EULAR). Results: The physicians surveyed cared for a median of 10 patients (interquartile range 6---30) with giant cell arteritis during their practice. As a diagnostic method, respondents used tempo- ral artery biopsy (84%), temporal artery ultrasound (61%) or other imaging techniques (37%). As first-line therapy, respondents used high-dose glucocorticoids (at least 40 mg of prednisone, or equivalent, per day) (84%), glucocorticoids with methotrexate (7%) and glucocorticoids with tocilizumab (5%). The most frequent drugs used for relapse were methotrexate (37%) and tocilizumab (58%). Conclusion: Our results indicate that the medical specialists surveyed follow the recent EULAR recommendations for giant cell arteritis diagnosis and therapy
Autoría: M.A.González-Gay, N.Ortego-Centeno y L.Ercole
Fuente: Revista Clínica Española, 2022, 222(5), 266-271
Editorial: Doyma
Fecha de publicación: 01/05/2022
Nº de páginas: 6
Tipo de publicación: Artículo de Revista
DOI: 10.1016/j.rceng.2021.02.002
ISSN: 0014-2565,1578-1860
Url de la publicación: https://doi.org/10.1016/j.rceng.2021.02.002
Leer publicación
MIGUEL ANGEL GONZALEZ-GAY MANTECON
ORTEGO-CENTENO, N.
ERCOLE, L.
Volver